Bone is a dynamic organ where skeletal progenitors and hematopoietic cells share and compete for space. Presumptive mesenchymal stem cells (MSC) have been identified and harvested from the bone marrow (BM-MSC) and cortical bone fragments (CBF-MSC). In this study, we demonstrate that despite the cells sharing a common ancestor, the differences in the structural properties of the resident tissues affect cell behavior and prime them to react differently to stimuli. Similarly to the bone marrow, the cortical portion of the bone contains a unique subset of cells that stains positively for the common MSC-associated markers. These cells display different multipotent differentiation capability, clonogenic expansion, and immunosuppressive potential. In particular, when compared with BM-MSC, CBF-MSC are bigger in size, show a lower proliferation rate at early passages, have a greater commitment toward the osteogenic lineage, constitutively produce nitric oxide as a mediator for bone remodeling, and more readily respond to proinflammatory cytokines. Our data suggest that the effect of the tissue's microenvironment makes the CBF-MSC a superior candidate in the development of new strategies for bone repair.
Get full access to this article
View all access options for this article.
References
1.
BiancoP, RobeyPG and SimmonsPJ. (2008). Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell, 2:313–319.
2.
PittengerMF, MackayAM, BeckSC, JaiswalRK, DouglasR, MoscaJD, MoormanMA, SimonettiDW, CraigS and MarshakDR. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284:143–147.
3.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for cellular therapy position statement. Cytotherapy, 8:315–317.
4.
CaplanAI. (2007). Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol, 213:341–347.
5.
CaplanAI and DennisJE. (2006). Mesenchymal stem cells as trophic mediators. J Cell Biochem, 98:1076–1084.
6.
RenG, ZhangL, ZhaoX, XuG, ZhangY, RobertsAI, ZhaoRC and ShiY. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2:141–150.
7.
ChamberlainG, FoxJ, AshtonB and MiddletonJ. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells, 25:2739–2749.
8.
FriedensteinAJ, GorskajaJF and KulaginaNN. (1976). Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol, 4:267–274.
9.
FraserJK, WulurI, AlfonsoZ and HedrickMH. (2006). Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol, 24:150–154.
10.
VillaronEM, AlmeidaJ, Lopez-HolgadoN, AlcocebaM, Sanchez-AbarcaLI, Sanchez-GuijoFM, AlbercaM, Perez-SimonJA, San MiguelJF and Del CanizoMC. (2004). Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation. Haematologica, 89:1421–1427.
11.
GriffithsMJ, BonnetD and JanesSM. (2005). Stem cells of the alveolar epithelium. Lancet, 366:249–260.
12.
BeltramiAP, BarlucchiL, TorellaD, BakerM, LimanaF, ChimentiS, KasaharaH, RotaM, MussoE, et al. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 114:763–776.
13.
LovatiAB, CorradettiB, Lange ConsiglioA, RecordatiC, BonacinaE, BizzaroD and CremonesiF. (2011). Characterization and differentiation of equine tendon-derived progenitor cells. J Biol Regul Homeost Agents, 25(2 Suppl):S75–S84.
14.
HuangTF, ChenYT, YangTH, ChenLL, ChiouSH, TsaiTH, TsaiCC, ChenMH, MaHL and HungSC. (2008). Isolation and characterization of mesenchymal stromal cells from human anterior cruciate ligament. Cytotherapy, 10:806–814.
15.
SonciniM, VertuaE, GibelliL, ZorziF, DenegriM, AlbertiniA, WenglerGS and ParoliniO. (2007). Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med, 1:296–305.
16.
CorradettiB, MeucciA, BizzaroD, CremonesiF and Lange ConsiglioA. (2013). Mesenchymal stem cells from amnion and amniotic fluid in the bovine. Reproduction, 145:391–400.
17.
Lange-ConsiglioA, CorradettiB, BizzaroD, MagattiM, ResselL, TassanS, ParoliniO and CremonesiF. (2012). Characterization and potential applications of progenitor-like cells isolated from horse amniotic membrane. J Tissue Eng Regen Med, 6:622–635.
18.
Lange-ConsiglioA, MaggioV, PellegrinoL and CremonesiF. (2012). Equine bone marrow mesenchymal or amniotic epithelial stem cells as feeder in a model for the in vitro culture of bovine embryos. Zygote, 20:45–51.
19.
SarugaserR, LickorishD, BakshD, HosseiniMM and DaviesJE. (2005). Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells, 23:220–229.
20.
WeissML, MedicettyS, BledsoeAR, RachakatlaRS, ChoiM, MerchavS, LuoY, RaoMS, VelagaletiG and TroyerD. (2006). Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells, 24:781–792.
21.
CorradettiB, Lange-ConsiglioA, BaruccaM, CremonesiF and BizzaroD. (2011). Size-sieved subpopulations of mesenchymal stem cells from intervascular and perivascular equine umbilical cord matrix. Cell Prolif, 44:330–342.
22.
LiechtyKW, MacKenzieTC, ShaabanAF, RaduA, MoseleyAM, DeansR, MarshakDR and FlakeAW. (2000). Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med, 6:1282–1286.
23.
Le BlancK, RasmussonI, SundbergB, GotherstromC, HassanM, UzunelM and RingdenO. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363:1439–1441.
24.
PatelDM, ShahJ and SrivastavaAS. (2013). Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells Int 2013:Article ID. 496218.
25.
MurphyMB, MoncivaisK and CaplanAI. (2013). Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med, 45:e54
26.
CasiraghiF, NorisM and RemuzziG. (2010). Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. Curr Opin Organ Transplant, 15:731–737.
27.
HassR, KasperC, BohmS and JacobsR. (2011). Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 9:12
28.
IvanovaNB, DimosJT, SchanielC, HackneyJA, MooreKA and LemischkaIR. (2002). A stem cell molecular signature. Science, 298:601–604.
29.
Ramalho-SantosM, YoonS, MatsuzakiY, MulliganRC and MeltonDA. (2002). “Stemness”.: transcriptional profiling of embryonic and adult stem cells. Science, 298:597–600.
30.
YagiH, Soto-GutierrezA, ParekkadanB, KitagawaY, TompkinsRG, KobayashiN and YarmushML. (2010). Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant, 19:667–679.
31.
LiB, MoshfeghC, LinZ, AlbuschiesJ and VogelV. (2013). Mesenchymal stem cells exploit extracellular matrix as mechanotransducer. Sci R, 3:2425
32.
WattFM and HoganBL. (2000). Out of Eden: stem cells and their niches. Science, 287:1427–1430.
33.
SpradlingA, Drummond-BarbosaD and KaiT. (2001). Stem cells find their niche. Nature, 414:98–104.
34.
JonesDL and WagersAJ. (2008). No place like home: anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol, 9:11–21.
35.
FuchsE, TumbarT and GuaschG. (2004). Socializing with the neighbors: stem cells and their niche. Cell, 116:769–778.
36.
HonczarenkoM, LeY, SwierkowskiM, GhiranI, GlodekAM and SilbersteinLE. (2006). Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells, 24:1030–1041.
37.
KramperaM, CosmiL, AngeliR, PasiniA, LiottaF, AndreiniA, SantarlasciV, MazzinghiB, PizzoloG, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24:386–398.
38.
SakaguchiY, SekiyaI, YagishitaK, IchinoseS, ShinomiyaK and MunetaT. (2004). Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. Blood, 104:2728–2735.
39.
SottileV, HalleuxC, BassilanaF, KellerH and SeuwenK. (2002). Stem cell characteristics of human trabecular bone-derived cells. Bone, 30:699–704.
40.
TuliR, SeghatoleslamiMR, TuliS, WangML, HozackWJ, MannerPA, DanielsonKG and TuanRS. (2003). A simple, high-yield method for obtaining multipotential mesenchymal progenitor cells from trabecular bone. Mol Biotechnol, 23:37–49.
41.
TuliR, TuliS, NandiS, WangML, AlexanderPG, Haleem-SmithH, HozackWJ, MannerPA, DanielsonKG and TuanRS. (2003). Characterization of multipotential mesenchymal progenitor cells derived from human trabecular bone. Stem Cells, 21:681–693.
42.
ZhuH, GuoZK, JiangXX, LiH, WangXY, YaoHY, ZhangY and MaoN. (2010). A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat Protoc, 5:550–560.
43.
BiancoP. (2011). Minireview: the stem cell next door: skeletal and hematopoietic stem cell “niches”. in bone. Endocrinology, 152:2957–2962.
44.
HattnerR, EpkerBN and FrostHM. (1965). Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature, 206:489–490.
45.
TakayanagiH. (2007). Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol, 7:292–304.
46.
Negishi-KogaT and TakayanagiH. (2012). Bone cell communication factors and Semaphorins. BoneKEy Rep. 1183.
YinT and LiL. (2006). The stem cell niches in bone. J Clin Invest, 116:1195–1201.
49.
SoleimaniM and NadriS. (2009). A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc, 4:102–106.
50.
HegyiB, KudlikG, MonostoriE and UherF. (2012). Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells. Biochem Biophys Res Commun, 419:215–220.
51.
RoubelakisMG, PappaKI, BitsikaV, ZagouraD, VlahouA, PapadakiHA, AntsaklisA and AnagnouNP. (2007). Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev, 16:931–952.
52.
FoudahD, RedondoJ, CaldaraC, CariniF, TrediciG and MilosoM. (2012). Expression of neural markers by undifferentiated rat mesenchymal stem cells. J Biomed Biotechnol, 2012:820821
53.
Mendez-FerrerS, MichurinaTV, FerraroF, MazloomAR, MacarthurBD, LiraSA, ScaddenDT, Ma'ayanA, EnikolopovGN and FrenettePS. (2010). Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature, 466:829–834.
54.
EhningerA and TrumppA. (2011). The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med, 208:421–428.
55.
ThomsonTM, RettigWJ, ChesaPG, GreenSH, MenaAC and OldLJ. (1988). Expression of human nerve growth factor receptor on cells derived from all three germ layers. Exp Cell Res, 174:533–539.
56.
LeeCC, ChristensenJE, YoderMC and TarantalAF. (2010). Clonal analysis and hierarchy of human bone marrow mesenchymal stem and progenitor cells. Exp Hematol, 38:46–54.
57.
JonesEA, EnglishA, KinseySE, StraszynskiL, EmeryP, PonchelF and McGonagleD. (2006). Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry B Clin Cytom, 70:391–399.
58.
QuiriciN, SoligoD, BossolascoP, ServidaF, LuminiC and DeliliersGL. (2002). Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol, 30:783–791.
59.
MeyerroseTE, De UgarteDA, HoflingAA, HerrbrichPE, CordonnierTD, ShultzLD, EagonJC, WirthlinL, SandsMS, HedrickMA and NoltaJA. (2007). In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells, 25:220–227.
60.
WeissML and TroyerDL. (2006). Stem cells in the umbilical cord. Stem Cell Rev, 2:155–162.
61.
BentivegnaA, MilosoM, RivaG, FoudahD, ButtaV, DalpraL and TrediciG. (2013). DNA methylation changes during in vitro propagation of human mesenchymal stem cells: implications for their genomic stability?. Stem Cells Int, 2013:192425
62.
WiesmannA, BuhringHJ, MentrupC and WiesmannHP. (2006). Decreased CD90 expression in human mesenchymal stem cells by applying mechanical stimulation. Head Face Med, 2:28
63.
HayerS, SteinerG, GortzB, ReiterE, Tohidast-AkradM, AmlingM, HoffmannO, RedlichK, ZwerinaJ, et al. (2005). CD44 is a determinant of inflammatory bone loss. J Exp Med, 201:903–914.
RedaelliS, BentivegnaA, FoudahD, MilosoM, RedondoJ, RivaG, BaronchelliS, DalpraL and TrediciG. (2012). From cytogenomic to epigenomic profiles: monitoring the biologic behavior of in vitro cultured human bone marrow mesenchymal stem cells. Stem Cell Res Ther, 3:47
66.
HughesFJ, ButteryLD, HukkanenMV, O'DonnellA, MacloufJ and PolakJM. (1999). Cytokine-induced prostaglandin E2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and -independent mechanism in rat osteoblasts in vitro. J Biol Chem, 274:1776–1782.
67.
ZinockerS and VaageJT. (2012). Rat mesenchymal stromal cells inhibit T cell proliferation but not cytokine production through inducible nitric oxide synthase. Front Immunol, 3:62
68.
ZinockerS, WangMY, RolstadB and VaageJT. (2012). Mesenchymal stromal cells fail to alleviate experimental graft-versus-host disease in rats transplanted with major histocompatibility complex-mismatched bone marrow. Scand J Immunol, 76:464–470.
69.
Klein-NulendJ, van OersRF, BakkerAD and BacabacRG. (2013). Nitric oxide signaling in mechanical adaptation of bone. Osteoporos Int, 25:1427–1437.
70.
BurnstockG and ArnettTR. (2007). Nucleotides and Regulation of Bone Cell Function. CRC/Taylor & Francis, Boca Raton, FL, p. 207.
71.
KeilaS, KelnerA and WeinrebM. (2001). Systemic prostaglandin E2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro. J Endocrinol, 168:131–139.
72.
KuciS, KuciZ, KreyenbergH, DeakE, PutschK, HueneckeS, AmaraC, KollerS, RettingerE, et al. (2010). CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica, 95:651–659.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
